# Hippo Signaling in the Lung: A Tale of Two Effectors—Yap Drives Airway Fate and Taz Drives Alveolar Differentiation

## TL;DR

This paper explains how YAP and TAZ, two proteins in the Hippo signaling pathway, have distinct roles in lung development and disease, with YAP promoting airway growth and TAZ driving alveolar differentiation.

## Contribution

The paper introduces a 'Tale of Two Effectors' model, highlighting the non-redundant roles of YAP and TAZ in lung biology and disease.

## Key findings

- YAP drives airway progenitor expansion and maladaptive remodeling, while TAZ is essential for alveolar differentiation.
- The 'See-Saw' model explains how mesenchymal niche collapse leads to bronchiolization in pulmonary fibrosis.
- SCLC subtypes reflect developmental and regenerative states, with YAP1+ SCLC acting as a 'supercompetitor'.

## Abstract

What are the main findings?
YAP and TAZ exhibit functional non-redundancy in the lung: YAP drives airway progenitor expansion, while TAZ is the obligate driver of alveolar differentiation via an NKX2-1 feed-forward loop.The “See-Saw” and “Niche Collapse” models explain that “honeycombing” can be triggered by a loss of mesenchymal fitness, which releases a mechanical brake on the epithelium.

YAP and TAZ exhibit functional non-redundancy in the lung: YAP drives airway progenitor expansion, while TAZ is the obligate driver of alveolar differentiation via an NKX2-1 feed-forward loop.

The “See-Saw” and “Niche Collapse” models explain that “honeycombing” can be triggered by a loss of mesenchymal fitness, which releases a mechanical brake on the epithelium.

What is the implication of the main finding?
Classification of Small Cell Lung Cancer (SCLC) subtypes through a developmental lens identifies the YAP1+ (SCLC-Y) state as a “supercompetitor” that mirrors maladaptive regenerative states.Therapeutic strategies for fibrosis must move beyond anti-inflammatory approaches to focus on restoring niche fitness (e.g., Snail stabilization) and inhibiting the YAP-driven “supercompetitor” state.

Classification of Small Cell Lung Cancer (SCLC) subtypes through a developmental lens identifies the YAP1+ (SCLC-Y) state as a “supercompetitor” that mirrors maladaptive regenerative states.

Therapeutic strategies for fibrosis must move beyond anti-inflammatory approaches to focus on restoring niche fitness (e.g., Snail stabilization) and inhibiting the YAP-driven “supercompetitor” state.

The mammalian lung operates under a biological paradox, requiring architectural fragility for gas exchange while maintaining robust regenerative plasticity to withstand injury. The Hippo signaling pathway has emerged as a central “rheostat” in orchestrating these opposing needs, yet the distinct roles of its downstream effectors remain underappreciated. This review synthesizes recent genetic and mechanobiological advances to propose a “Tale of Two Effectors” model, arguing for the functional non-redundancy of YAP and TAZ. We posit that YAP functions to drive airway progenitor expansion, mechanical force generation, and maladaptive remodeling. Conversely, TAZ—regulated uniquely via transcriptional mechanisms and mechanotransduction—acts as an obligate driver of alveolar differentiation and adaptive repair through an NKX2-1 feed-forward loop. Furthermore, we introduce the “See-Saw” model of tissue fitness, where mesenchymal niche collapse releases the mechanical brake on the epithelium, triggering the bronchiolization characteristic of pulmonary fibrosis. Finally, we extend this framework to malignancy, illustrating how Small Cell Lung Cancer (SCLC) subtypes mirror these developmental and regenerative states. This integrated framework offers new therapeutic distinct targets for modulating tissue fitness and resolving fibrosis.